Corporate Snapshot
Tapestry Pharmaceuticals, Inc. ("Tapestry" or "the Company") is a biopharmaceutical company developing New Chemical Entities that may be effective in treating a broad spectrum of cancers. The Company's lead compound, TPI 287, is a novel, proprietary, third-generation taxane. Although taxanes have been used as cancer therapies for many years, treatment with these drugs is often plagued by undesirable effects, the most notable being the emergence of multi-drug resistance (MDR). To address this, Tapestry is developing TPI 287, which has shown the ability to overcome MDR in preclinical experiments. In particular, TPI 287 targets MDR-1 (the primary mechanism responsible for tumor resistance to taxanes). TPI 287 has also shown efficacy in preclinical studies in a broad range of cell lines versus comparator drugs. Furthermore, in animal models, TPI 287 has shown greater oral bioavailability than paclitaxel, an approved taxane. The Company filed an Investigational New Drug (IND) application for TPI 287 with the U.S. Food and Drug Administration (FDA) and commenced two Phase 1 studies, each with a different dosing regimen. The first Phase 1 study, which began in January 2005, employed a Q7D X3 regimen (dosing every seven days for three weeks), while the second Phase 1 study, which started in January 2006, used a Q21D (dosing every 21 days) regimen. The objectives of these Phase 1 trials were to determine the maximum tolerated dose (MTD) to be used in Phase 2 studies as well as to determine the safety, anti-tumor, and pharmacokinetic and pharmacodynamic profiles of TPI 287. In October 2006, the Company reached the MTD of its second Phase 1 trial. The Company is headquartered in Boulder, Colorado, with offices in New Jersey and New York.
* The Corporate Snapshot was last updated on September 7, 2007.
Latest Research
Executive
Informational
Overview
2007-09-07
Click to View